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Abstract
Background: Transient receptor potential (TRP) vanilloid and ankyrin cation channels are activated by various
noxious chemicals and may play an important role in the pathogenesis of cough. The aim was to study the
influence of single nucleotide polymorphisms (SNPs) in TRP genes and irritant exposures on cough.
Methods: Nocturnal, usual, and chronic cough, smoking, and job history were obtained by questionnaire in 844
asthmatic and 2046 non-asthmatic adults from the Epidemiological study on the Genetics and Environment of
Asthma (EGEA) and the European Community Respiratory Health Survey (ECRHS). Occupational exposures to
vapors, gases, dusts, and/or fumes were assessed by a job-exposure matrix. Fifty-eight tagging SNPs in TRPV1,
TRPV4, and TRPA1 were tested under an additive model.
Results: Statistically significant associations of 6 TRPV1 SNPs with cough symptoms were found in non-asthmatics after
correction for multiple comparisons. Results were consistent across the eight countries examined. Haplotype-based
association analysis confirmed the single SNP analyses for nocturnal cough (7-SNP haplotype: p-global = 4.8 × 10
-6)a n d
usual cough (9-SNP haplotype: p-global = 4.5 × 10
-6). Cough symptoms were associated with exposure to irritants such
as cigarette smoke and occupational exposures (p < 0.05). Four polymorphisms in TRPV1 further increased the risk of
cough symptoms from irritant exposures in asthmatics and non-asthmatics (interaction p < 0.05).
Conclusions: TRPV1 SNPs were associated with cough among subjects without asthma from two independent
studies in eight European countries. TRPV1 SNPs may enhance susceptibility to cough in current smokers and in
subjects with a history of workplace exposures.
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Background
TRPV1, TRPV4, and TRPA1 cation channels are mem-
bers of the vanilloid (TRPV) and ankyrin (TRPA) sub-
family of transient receptor potential channels. These
channels are expressed in different cells of the lung,
including sensory neurons participating in airway reflex
responses, bronchial smooth muscle, and epithelial and
endothelial cells [1,2]. TRPV1 channels are activated by
capsaicin, heat, particulate matter, and various noxious
chemicals, and are upregulated in airway nerves and air-
ways smooth muscle of individuals with cough [1-4]. It
has recently been shown that the TRPV1 Ile585Val single
nucleotide polymorphism (SNP) results in a loss-of-chan-
nel function, and that this SNP is associated with a lower
risk of cough and wheezing among children with asthma
[5]. TRPA1 acts as a receptor for a wide range of irritants
and chemicals, including air pollutants and some of the
principal components of cigarette smoke [6,7]. Agonists of
TRPV1 and TRPA1 channels can elicit a reproducible
cough response in humans [8,9], and induce neurogenic
inflammatory responses in experimental models [7,10,11].
TRPV1 and TRPA1 have been put forward as major
targets for novel anti-tussive drugs [12,13].
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disease through regulation of endothelial and epithelial
permeability in the lungs, bronchial smooth muscle cell
contractility, and mucociliary transport [14-17]. TRPV4
dysfunction has already been associated to airway dis-
eases: airway epithelial cells from cystic fibrosis patients
show a defective regulation of TRPV4 [18,19], and SNPs
in the TRPV4 gene have been found to be associated with
chronic obstructive pulmonary disease (COPD) [20].
Because of the central role of TRP channels in cough
response, we hypothesized that variants in genes encoding
TRP channels may be associated with cough symptoms.
Moreover, given the critical involvement of TRP channels
in irritant sensing, TRP variants may be particularly rele-
vant for irritant-induced cough [21]. Exposures to irritants,
for instance in cigarette smoke, or in exposures at work
can lead to a spectrum of asthma-related symptoms,
including cough [21]. In recent years, studies on asthma
and chronic cough symptoms in workers exposed to irri-
tant cleaning products have raised interest in chronic or
repeated exposures to relatively low levels of irritants
[22-24]. However, little is known about the mechanisms
implicated in irritant-induced airway disease.
We aimed to study association of SNPs in candidate
genes TRPV1, TRPV4, and TRPA1 with cough symptoms.
In addition, we explored whether TRP variants modulate
associations between occupational exposures and cough
symptoms, or between smoking and cough symptoms.
The study was carried out in adults from the French
Epidemiological study on the Genetics and Environment
of Asthma (EGEA) and from the European Community
Respiratory Health Survey (ECRHS).
Methods
Study population and design
EGEA is a case-control and a family study of asthma [25].
The population comprises individuals with asthma aged
7-70 who were recruited from six chest clinics in five
French cities, population-based control subjects, and
relatives of asthmatic probands (either the proband’s par-
ents and siblings, or the proband’s spouse and children).
In the present analysis, only genetically unrelated adults
aged 27-70 from the parental generation (adults with
asthma and spouse, or the parents of an individual with
asthma) were included, as described in detail elsewhere
[26].
The methodology of ECRHS has been described else-
w h e r e[ 2 7 ] .B r i e f l y ,t h eE C R H Si sar a n d o mp o p u l a t i o n -
based multicentre cohort from sixteen centers (eight
countries with DNA samples) of subjects aged 20-44 at
time of recruitment (1990, ECRHS-I) and then followed-
up approximately 10 years later (ECRHS-II). In addition to
the random sample, a complementary, enriched sample of
subjects with asthma symptoms at recruitment but who
had not been selected at random to take part in ECRHS-II
was also included in the study and follow-up. All asthma
cases and a random sample of subjects without asthma
were genotyped [28].
In total, 689 subjects from EGEA and 2201 subjects
from ECRHS with complete questionnaire and TRP gen-
otyping data were included in the present analysis (844
subjects with asthma, 2046 subjects without asthma).
Additional file 1: Figures S1 and S2 present a flow chart
of the study population. Ethical approval was obtained
for EGEA and for each ECRHS centre from the appropri-
ate institutional ethics committee and written consent
was obtained from each participant.
Questionnaire
Identical questions were used to assess cough symptoms,
job history, and smoking in both studies [29]. Nocturnal
cough was defined as a positive answer to the question
“Have you been woken by an attack of coughing at any
time in the last 12 months?”. Usual cough was defined as
a positive answer to the question “Do you usually cough
first thing in the morning in the winter?” or “Do you
usually cough during the day, or at night, in the winter?”.
Chronic cough was defined as usual cough and a positive
answer to “Do you cough like this on most days for as
much as three months each year?”. The role of recent
respiratory infections (like a common cold) in cough
symptoms was studied by the question “Have you had a
respiratory infection in the last 3 weeks?”. The definition
of (ever) asthma in both studies is given in the Additional
File. Smoking was defined as described earlier [29,30],
and subjects were categorized into three classes: current
smokers, ex smokers and never smokers. Subjects
reported their two most recent jobs, which were coded
according to international standard classification of occu-
pations (ISCO-88). Jobs were linked to low or high expo-
sure to biological dust, mineral dust, and vapors, gases,
or fumes using the ALOHA job-exposure matrix (JEM)
[31]. Occupational exposure to vapors, gases, dusts, and/
or fumes (VGDF) was defined as low or high exposure to
any VGDF in at least one job. More details are given in
the Additional File.
Genotyping
A preliminary candidate gene study on TRPV1 and TRPV4
was conducted earlier in EGEA [32]. To enable replication,
we used genome-wide genotyping of all EGEA and ECRHS
subjects from the Gabriel consortium genome-wide asso-
ciation study [28], and we included TRPA1 as an additional
candidate gene. All SNPs within the gene region (at least
10 kb upstream of the 5’ end through 5 kb downstream of
the 3’ end according to the HapMap database) were
selected from the Illumina Human610 quad array panel
[28]. Nineteen SNPs in TRPV1 (located at chromosome
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TRPA1 (8q13) were studied. These SNPs fulfilled the qual-
ity control criteria that have been applied to the Gabriel
study (see Additional File) [28], and allowed us to capture
the majority of common haplotype variations of the three
genes (i.e., haplotype with a frequency ≥ 5%). Additional
Figures E3, E4, and E5 show linkage disequilibrium (LD)
between SNPs for the three genes.
Statistical analysis
Statistical analysis is described in detail in the Additional
File. The EGEA and ECRHS study populations were
pooled to increase statistical power, and consistency of
results was verified by analyzing both studies separately
and by performing a random effects meta-analysis of
EGEA and the eight ECRHS country-specific samples.
The latter allowed to test for heterogeneity across sam-
ples. Analyses were conducted in subjects with and with-
out asthma separately, because cough is associated with
asthma, and EGEA subjects were recruited through asth-
matic patients. The effect of single SNPs on cough was
tested under an additive genetic model with the minor
allele as risk allele, as was done in previous studies that
have shown associations between TRPV SNPs and
respiratory outcomes [5,20]. Subjects without the given
cough symptom were studied as the reference group.
Population admixture was taken into account by includ-
ing informative principal components for within-Europe
diversity for EGEA and ECRHS as covariates in the asso-
ciation analysis [28]. Age, smoking, sex, occupational
exposure, study and sample (dummy indicators for
EGEA, random sample ECRHS, and symptomatic sample
of ECRHS) were also incorporated in the logistic model.
P-values of association were corrected to address multi-
ple testing (n = 174 tests, i.e. 58 SNPs × 3 cough out-
comes) using the Benjamini-Hochberg method [33].
Haplotype association analyses were assessed using
SNPassoc [34] and haplo.stats [35] R packages, and we
further used an unbiased sliding window approach to
construct successive and adjacent 2- to 9-SNPs haplo-
types. To explore whether the effect of occupational
exposure or current smoking on cough was modified by
TRP genotype we introduced a multiplicative gene-envir-
onment interaction term in the model (SNP × occupa-
tional exposure or SNP × current smoking). The
statistical significance of the interaction term was
assessed by using a generalized score test which follows a
chi-square distribution with 1 degree of freedom.
Results
Personal characteristics and the prevalence of cough
symptoms of the study population are shown in Table 1.
Any type of cough was reported by 60.0% of subjects
with asthma, and 33.7% of subjects without asthma.
Among subjects with asthma, 25.8% reported both noc-
turnal cough and usual cough, 22.0% reported nocturnal
cough but no usual cough, and 12.2% reported usual
cough but no nocturnal cough. For subjects without
asthma, these prevalence rates were 8.3%, 18.0%, and
7.4%, respectively. Women were less often exposed to
VGDF than men, and were more often never smokers
( p<0 . 0 1 ) .E x p o s u r et oV G D Fw a sn o ta s s o c i a t e dw i t h
asthma (OR 0.99 [0.81-1.21]), and this association did
not differ between men and women.
Occupational exposures, smoking and cough symptoms
In subjects with asthma, female gender was significantly
associated with all cough symptoms, and current smok-
ing was associated with usual cough and chronic cough
(Table 2). When current smokers were stratified by med-
ian cigarette consumption (16 pack-years), the associa-
tion was only observed for heavy smokers. Occupational
exposure to VGDF was significantly associated with noc-
turnal cough (OR 1.39 [1.04-1.87]) and chronic cough
(OR 1.69 [1.18-2.43]). Respiratory infection during the
last 3 weeks was only significantly associated with an
increased prevalence of nocturnal cough. In subjects
without asthma, nocturnal cough was more prevalent
among female subjects, and current smoking was asso-
ciated with all cough symptoms. The association was
stronger for heavy smokers but statistically significant
also for light smokers. Respiratory infection was posi-
tively and significantly associated with nocturnal cough
and usual cough. No association between occupational
exposure and cough symptoms was found (Table 2).
Although the pattern of determinants was similar in both
studies, associations with occupation in asthmatics
tended to be stronger in EGEA (chronic cough: OR 2.82
[1.39-5.72]) than in ECRHS (OR 1.34 [0.87-2.07])
Association analysis TRP polymorphisms and cough
In subjects without asthma, 10 TRPV1 SNPs were asso-
ciated with nocturnal cough (4.3 × 10
5 ≤ p ≤ 0.044),
6 TRPV1 SNPs were associated with usual cough (2.0 ×
10
-5 ≤ p ≤ 0.046), and 4 TRPV1 SNPs were associated
with chronic cough (0.005 ≤ p ≤ 0.045) (Table 3). After
adjustment for multiple testing, 7 associations between
TRPV1 SNPs and cough symptoms remained statistically
significant (Table 3). All associations between TRPV1
SNPs and cough that were significant in the pooled ana-
lysis (after correction for multiple testing) showed the
same direction of association in ECRHS and EGEA
(Additional file 1: Table S1 and S2). Seven associations
were statistically significant in both studies. We esti-
mated a summary OR for these SNPs using a random
effects meta-analysis applied to EGEA and the separate
ECRHS countries (Figure 1). The OR estimates from the
pooled analysis and random effects meta-analysis were
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the different countries for the association between usual
cough and TRPV1 rs17706630 (p heterogeneity = 0.932)
and rs2277675 (p = 0.886) and consistency for the asso-
ciation between TRPV1 rs17706630 (p = 0.162),
rs2277675 (p = 0.275), and rs224498 (p = 0.542) and noc-
turnal cough, whereas heterogeneity was observed for the
association between two TRPV1 SNPs and nocturnal
cough (rs161365; p = 0.048 and rs150854; p = 0.040).
The associations between TRPV1 SNPs and cough
symptoms did not differ between men and women (p for
interaction > 0.05 for all SNPs). Further, excluding those
with FEV1 < 80% predicted did not change the results.
In subjects with asthma, two TRPV1 SNPs were asso-
ciated with usual cough, but the associations did not
remain significant after correction for multiple testing
(Table 3). Associations between SNPs in TRPV4 and
TRPA1 and cough symptoms in subjects with or without
asthma were also not significant after adjusting for mul-
tiple testing (Additional file 1: Tables S3 and S4).
Table 1 Characteristics of the study population
Asthma No asthma
Men Women P value Men Women P value
n
Study, n (%)
368 476 1008 1038
EGEA 107 (29.1) 96 (20.2) 248 (24.6) 238 (22.9)
ECRHS 261 (70.9) 380 (79.8) 760 (75.4) 800 (77.1)
Age, mean (sd)
Smoking habits, n (%)
44.4 (8.3) 42.2 (7.4) 0.006 44.1 (7.7) 43.9 (7.5) 0.65
Never smokers 141 (38.3) 232 (48.7) 0.004 372 (36.9) 515 (49.6) < 0.001
Ex smokers 130 (35.3) 125 (26.3) 278 (27.6) 237 (22.8)
Current smokers 97 (26.4) 119 (25.0) 358 (35.5) 286 (27.6)
≤ 16 pack-years 36 (9.8) 66 (13.9) 121 (12.0) 150 (14.5)
> 16 pack-years 49 (13.3) 40 (8.4) 188 (18.7) 88 (8.5)
pack-years unknown 12 (3.3) 13 (2.7) 49 (4.9) 48 (4.6)
Exposure to VGDF, n(%)*
Cough symptoms, n(%)
182 (51.0) 182 (39.8) 0.002 544 (55.0) 361 (36.0) < 0.001
Nocturnal cough 131 (35.7) 272 (57.1) < 0.001 226 (22.4) 314 (30.3) < 0.001
Usual Cough 123 (33.6) 195 (41.4) < 0.001 167 (16.6) 152 (14.7) 0.23
Chronic cough 64 (17.7) 103 (22.1) 0.12 73 (7.3) 52 (5.1) 0.03
Respiratory infection last 3 weeks, n (%) 52 (14.4) 54 (11.5) 0.21 87 (8.7) 80 (7.8) 0.57
*VGDF: vapours, gases, dust, or fumes
Overall, out of 1157 subjects with any type of cough, 550 had nocturnal only (47.5%), 150 usual cough only (13.0%), 92 chronic cough (7.9%), 165 usual and
nocturnal (14.3%) and 200 chronic and nocturnal (17.3%)
Twenty-eight subjects had missing values for one of the cough variables. Forty-two subjects had missing values for the infection variable
Table 2 Determinants of nocturnal cough, usual cough, and chronic cough in 844 adults with asthma and in 2046
adults without asthma
Subjects with asthma Subjects without asthma
Nocturnal cough Usual cough Chronic cough Nocturnal cough Usual cough Chronic cough
Female sex 2.85 (2.10-3.86) 1.42 (1.05-1.93) 1.49 (1.02-2.17) 1.67 (1.35-2.07) 0.95 (0.73-1.23) 0.78 (0.53-1.16)
Exposure to VGDF* 1.39 (1.04-1.87) 1.29 (0.96-1.73) 1.69 (1.18-2.43) 1.09 (0.88-1.35) 0.98 (0.75-1.27) 1.05 (0.70-1.56)
Age, per 10 y 1.17 (0.96-1.42) 1.10 (0.90-1.34) 1.16 (0.90-1.48) 1.04 (0.91-1.21) 1.10 (0.91-1.32) 1.16 (0.88-1.54)
Ex smoker vs. never smoker 0.89 (0.62-1.26) 0.86 (0.60-1.24) 0.65 (0.40-1.05) 1.11 (0.85-1.46) 0.94 (0.64-1.37) 1.07 (0.57-2.01)
Current smoker vs. never smoker 1.15 (0.80-1.66) 2.04 (1.43-2.91) 2.12 (1.40-3.21) 1.68 (1.32-2.14) 3.37 (2.53-4.49) 4.26 (2.67-6.79)
≤ 16 pack-years vs. never smoker† 1.03 (0.64-1.64) 1.08 (0.67-1.74) 1.13 (0.63-2.02) 1.28 (0.93-1.76) 2.18 (1.49-3.19) 2.31 (1.24-4.33)
> 16 pack-years vs. never smoker† 1.44 (0.87-2.39) 4.45 (2.66-7.45) 3.71 (2.20-6.27) 2.34 (1.71-3.20) 5.18 (3.66-7.34) 6.43 (3.79-10.92)
Respiratory infection last 3 weeks 1.84 (1.18-2.87) 1.17 (0.76-1.82) 1.13 (0.68-1.90) 2.45 (1.74-3.44) 1.51 (1.00-2.29) 1.54 (0.84-2.83)
Multivariate GEE model, adjusted for all variables in the table, principal components for within-Europe diversity, sample, and study; results are presented as OR
(95% CI). Bold type indicates P < 0.05
*VGDF: vapours, gases, dust, or fumes
† in models without current smoker vs. never smoker. Coefficients for all other variables were basically similar (e.g.OR were for nocturnal cough 2.57, 1.27, 1.15,
0.89 and 1.67, 1.06, 1.01 and 1.13 for sex, VGDF, age and ex-smoker in subjects with and without asthma respectively)
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Page 4 of 11Table 3 Association of TRPV1 SNPs with nocturnal cough, usual cough, and chronic cough under an additive model in 844 adults with asthma and 2046
adults without asthma
Subjects with asthma Subjects without asthma
SNP Region Alleles
† MAF Nocturnal cough Usual cough Chronic cough Nocturnal cough Usual cough Chronic cough
rs4790522 3’UTR C/A 0.41 0.97 (0.78-1.20) 1.35 (1.09-1.67) 1.19 (0.92-1.55) 1.20 (1.03-1.39) 1.31 (1.10-1.57) 1.01 (0.77-1.31)
rs16953163 intron A/G 0.20 0.95 (0.73-1.23) 0.83 (0.64-1.09) 0.81 (0.58-1.12) 1.10 (0.92-1.30) 1.08 (0.88-1.34) 1.15 (0.84-1.57)
rs224546 intron T/C 0.42 0.96 (0.77-1.18) 1.27 (1.03-1.58) 1.07 (0.83-1.39) 1.16 (1.00-1.35) 1.09 (0.91-1.30) 0.89 (0.68-1.15)
rs11655540 intron T/G 0.35 1.03 (0.83-1.28) 0.89 (0.71-1.10) 1.03 (0.79-1.34) 0.77 (0.66-0.90) * 0.85 (0.70-1.03) 1.09 (0.83-1.43)
rs161364 intron C/T 0.28 0.93 (0.73-1.17) 1.12 (0.89-1.42) 1.11 (0.84-1.47) 1.09 (0.93-1.29) 1.22 (1.01-1.49) 1.13 (0.84-1.52)
rs8065080 Ile585Val T/C 0.39 0.94 (0.76-1.15) 0.94 (0.76-1.15) 0.91 (0.70-1.18) 1.15 (0.99-1.33) 0.92 (0.77-1.10) 0.90 (0.69-1.19)
rs161365 intron C/T 0.32 1.11 (0.89-1.39) 0.91 (0.73-1.15) 0.86 (0.66-1.13) 0.72 (0.62-0.85)*
‡ 0.85 (0.70-1.05) 1.02 (0.76-1.38)
rs150908 intron G/A 0.44 0.87 (0.71-1.07) 1.00 (0.81-1.23) 0.94 (0.73-1.20) 1.10 (0.95-1.28) 1.23 (1.03-1.48) 1.21 (0.93-1.58)
rs224534 Thr469Ile G/A 0.35 0.86 (0.69-1.06) 0.90 (0.73-1.11) 0.97 (0.76-1.25) 1.01 (0.87-1.18) 1.14 (0.96-1.36) 1.24 (0.96-1.61)
rs17706630 intron G/A 0.27 1.02 (0.81-1.30) 0.95 (0.75-1.21) 1.00 (0.76-1.32) 0.71 (0.59-0.84)*
‡ 0.73 (0.59-0.92)
‡ 0.71 (0.50-0.99)
rs222748 His167His G/A 0.11 1.00 (0.72-1.40) 0.92 (0.66-1.28) 1.20 (0.82-1.76) 0.97 (0.76-1.23) 1.18 (0.89-1.56) 1.32 (0.88-1.97)
rs150846 intron G/A 0.36 1.12 (0.91-1.38) 1.08 (0.87-1.33) 1.11 (0.85-1.44) 1.22 (1.05-1.41) 1.18 (0.99-1.42) 1.25 (0.96-1.62)
rs2277675 5’UTR T/C 0.28 1.17 (0.93-1.46) 0.97 (0.77-1.21) 1.04 (0.79-1.35) 0.73 (0.62-0.86)*
‡ 0.64 (0.52-0.80)*
‡ 0.64 (0.46-0.90)
rs161381 5’UTR G/T 0.15 1.05 (0.79-1.39) 1.21 (0.91-1.61) 1.06 (0.75-1.50) 1.20 (0.98-1.47) 1.19 (0.93-1.51) 1.07 (0.75-1.55)
rs222738 5’UTR C/T 0.09 0.99 (0.69-1.40) 0.93 (0.64-1.33) 1.14 (0.73-1.77) 0.84 (0.65-1.09) 1.12 (0.82-1.51) 1.37 (0.89-2.09)
rs17707155 5’UTR C/T 0.28 0.91 (0.73-1.14) 0.97 (0.77-1.21) 0.99 (0.75-1.31) 1.23 (1.05-1.43) 1.01 (0.83-1.22) 1.05 (0.78-1.40)
rs222741 5’ A/G 0.24 1.07 (0.85-1.34) 1.15 (0.90-1.46) 1.11 (0.83-1.50) 1.10 (0.93-1.30) 1.23 (1.01-1.51) 1.40 (1.04-1.88)
rs150854 5’ T/G 0.46 1.12 (0.91-1.37) 0.96 (0.78-1.18) 0.94 (0.73-1.21) 0.74 (0.64-0.86)*
‡ 0.84 (0.70-1.00) 0.76 (0.57-1.00)
rs224498 5’ T/G 0.39 0.93 (0.76-1.15) 1.16 (0.94-1.43) 0.99 (0.76-1.27) 1.32 (1.14-1.53)*
‡ 1.11 (0.92-1.33) 1.00 (0.76-1.31)
Results are presented as OR (95% CI) adjusted for age, sex, smoking habits, occupational exposure, principal components for within-Europe diversity, study, and sample
Bold type indicates P < 0.05, * P-value adjusted for multiple comparisons < 0.05.
† Major/minor allele. MAF, minor allele frequency.
‡ P < 0.05, both in EGEA and ECRHS
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1Haplotype-based association analysis TRPV1 and cough
Pairwise LD (r
2) between the TRPV1 SNPs that were
associated with cough symptoms was ≤ 0.72 (Additional
file 1: Figure S3). We performed a sliding window
approach to construct haplotypes across combinations
of successive SNPs that were associated with nocturnal
cough and usual cough in subjects without asthma. The
best result for nocturnal cough was a 7-SNP haplotype
comprising adjacent SNPs from rs8065080 to rs150846
(p-global = 4.8 × 10
-6, Additional file 1: Figure S6). For
Figure 1 Forest plots of odds ratios (OR) for SNPs associated with nocturnal or usual cough in both EGEA and ECRHS, according to
study and country (ECRHS). Summary ORs were calculated using a random effects meta-analysis applied to EGEA and the separate ECRHS
countries. Summary ORs (95% CI) for the association between rs17706630 and rs2277675 and usual cough were 0.72 (0.57-0.91) and 0.64 (0.51-
0.81), respectively. Summary ORs (95% CI) for the association between rs161365, rs17706630, rs2277675, rs150854, and rs224498 and nocturnal
cough were 0.72 (0.55-0.94), 0.69 (0.54-0.88), 0.71 (0.58-0.88), 0.72 (0.56-0.92), and 1.34 (1.14-1.58), respectively. ORs for associations with usual
cough could not be estimated for Switzerland, and ORs for nocturnal cough could not be estimated for the United Kingdom (UK)
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Page 6 of 11usual cough, a 9-SNP haplotype comprising adjacent
SNPs from rs17706630 to rs150854 showed the most
significant association (p-global = 4.5 × 10
-6, Additional
file 1: Figure S7). Tables 4 and 5 show association analy-
sis of specific TRPV1 haplotypes and nocturnal cough
and usual cough, respectively. The haplotype analysis
supported the results obtained by single SNP analysis.
Gene-environment interactions between TRPV1
polymorphisms and occupational exposure or smoking
We explored whether the effect of occupational exposure
or current smoking on cough was enhanced by SNPs in
TRPV1 because consistent main effects on cough symp-
toms were observed for this gene. In subjects without
asthma, three TRPV1 SNPs appeared to modify the asso-
ciation between current smoking and cough symptoms
(9.0 × 10
-4 ≤ p interaction ≤ 0.030; Additional file 1: Table
S5). In subjects with asthma, the association between
occupational exposure and usual cough and chronic
cough appeared to be modified by TRPV1 rs224498. Posi-
tive and significant associations between occupational
exposure and cough were observed among TT subjects
(OR 1.82 [1.11-2.99] for usual cough; OR 2.58 [1.39-4.79]
for chronic cough), whereas ORs were close to unity and
not statistically significant among GT subjects and GG
subjects (p interaction = 0.006 for usual cough and p =
0.025 for chronic cough).
Discussion
The present study showed significant associations
between TRPV1 SNPs and cough symptoms among sub-
jects without asthma from two independent European
studies. Although we carried out a pooled analysis to
increase the power of detecting associations of SNPs with
cough symptoms, we verified that the results were similar
in the EGEA and ECRHS studies, and reached the 5%
significance level for five SNPs in each study. Random-
effects meta-analysis of these SNPs showed similar esti-
mates of the summary ORs with those obtained from the
pooled analysis and no evidence of heterogeneity across
the different studies and countries involved for three of
these SNPs. Haplotype-based association analysis con-
firmed the single SNP analyses, and global p-values for
association between TRPV1 haplotypes and cough were
highly significant (p < 5 × 10
-6).
The functional relevance of these TRPV1 SNPs, or var-
iants not genotyped but in high LD with one of these
SNPs, is so far unknown. TRPV1 variants could result in
either activity or expression changes of TRPV1 channels
in airway nerves or airways smooth muscle, influencing
sensitivity for TRPV1-activating agents among carriers of
such a variant. In a recent report, Cantero-Recasens et al.
[5] have shown that a isoleucine-to-valine mutation at
position 585 of the TRPV1 protein results in a 20-30%
loss of channel function, and that the corresponding
TRPV1 I585V (rs8065080) SNP is associated with a sig-
nificantly lower risk of wheeze and cough in children
with asthma. The structural explanation for the altered
activity of TRPV1 585 V is not known at present, and
channel activity of other TRPV1 variants needs to be
evaluated. In the present analysis, TRPV1 I585V was also
associated with a lower risk of nocturnal cough in EGEA
adults with asthma (OR 0.62 [0.40-0.96], p = 0.03), but
the association was not statistically significant in the
pooled analysis. We did not find evidence of an associa-
tion between common TRPA1 or TRPV4 variants and
cough. The lack of association between SNPs in TRPA1
and cough was especially surprising, since many ubiqui-
tous environmental irritants have been shown to activate
TRPA1 receptors to cause cough [13,21]. The significant
associations of TRPV1 variants with cough imply that
our study population was large enough to reveal moder-
ately increased or decreased risk estimates, suggesting
Table 4 Haplotype-based association analysis of TRPV1
haplotypes and nocturnal cough in 2046 subjects
without asthma
Haplotype Haplotype frequency OR (95%CI) P value
TTGGAGG 0.227 1.00 (reference)
CCAAGGG 0.131 1.26 (0.97-1.64) 0.085
CCGGGGA 0.120 1.54 (1.18-2.02) 0.001*
TCAAGGG 0.090 1.40 (1.04-1.90) 0.027
TCAGGGA 0.087 1.55 (1.14-2.10) 0.004*
CCGGGGG 0.079 1.51 (1.10-2.05) 0.010
TCAAGAA 0.061 1.53 (1.08-2.16) 0.016
Rare haplotypes 0.205 1.19 (0.93-1.53) 0.161
Haplotypes are a combination of 7 adjacent SNPs: rs8065080 T/C - rs161365
C/T - rs150908 G/A - rs224534 G/A - rs17706630 G/A - rs222748 G/A -
rs150846 G/A. OR and 95% CI are adjusted for age, sex, smoking habits,
occupational exposure, principal components for within-Europe diversity,
study, and sample. *Significant after Bonferroni correction (0.05/7 = 0.007)
Table 5 Haplotype-based association analysis of TRPV1
haplotypes and usual cough in 2046 subjects without
asthma
Haplotype Haplotype frequency OR (95%CI) P value
AGGCGCCAG 0.224 1.00 (reference)
GGGTGCTAT 0.158 1.25 (0.92-1.71) 0.152
GGGTGCCAG 0.140 1.53 (1.13-1.08) 0.006*
GGATTCCGT 0.123 1.54 (1.11-2.14) 0.010
GGATGCTAT 0.099 1.24 (0.87-1.77) 0.241
GAATGTCGT 0.070 1.60 (1.09-2.35) 0.016
Rare haplotypes 0.186 1.15 (0.84-1.58) 0.382
Haplotypes are a combination of 9 adjacent SNPs: rs17706630 G/A - rs222748
G/A - rs150846 G/A - rs2277675 T/C - rs161381 G/T - rs222738 C/T -
rs17707155 C/T - rs222741 A/G - rs150854 T/G. OR and 95% CI are adjusted
for age, sex, smoking habits, occupational exposure, principal components for
within-Europe diversity, study, and sample. *Significant after Bonferroni
correction (0.05/6 = 0.0083)
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of power in our study. Our study was the first to explore
associations of TRPA1 variants and respiratory outcomes.
We cannot exclude the possibility that other respiratory
outcomes such as bronchial hyperresponsiveness or more
specific (irritant-induced) cough phenotypes are asso-
ciated with these variants. Moreover, other unidentified
rare genetic variants in TRPA1 or TRPV4 may play a role.
TRPV1 and TRPA1 are prime candidate genes for
gene-environment interactions with exposures to a wide
range of irritants and chemicals that may be encoun-
tered in the workplace, but also in air pollution and in
cigarette smoke. The present findings seem to support
this hypothesis by suggesting that interactions between
TRPV1 SNPs and occupational exposures and smoking
may modify the risk of cough symptoms. However,
given the large number of tests performed, our findings
on gene-environment interaction should be taken cau-
tiously. Our observation that TRPV1 variants interact
with irritants that may be present in occupational expo-
sures or cigarette smoke to increase the risk of cough
symptoms needs replication in other epidemiological or
functional studies.
Chronic cough is one of the most frequent reasons for
consultation with a primary care or respiratory physician,
and may cause important adverse psychosocial and physi-
cal effects on patients’ q u a l i t yo fl i f e[ 3 6 ] .T h e r ei sa n
unmet need for effective anti-tussive drugs for cough
patients [37]. TRPV1 is being pursued as one of the
potential therapeutic targets, and TRPV1 antagonists are
being developed [13,37]. The results of our genetic asso-
ciation study seem to support the hypothesis that modu-
lation of TRPV1 channel activity may provide therapeutic
benefit in cough. However, some TRPV1 antagonists
cause significant side effects on body temperature, which
has necessitated the withdrawal of these compounds
from clinical trials [13]. To date, both the scientific com-
munity and pharmaceutical industry are centered in the
finding of a TRPV1 modulator to treat pain, without
affecting temperature homeostasis. Potentially, the find-
ing of such a modulator could be used as an antitussive
agent.
Although cough is frequently associated with asthma
[29], it has also been shown that in a general population,
chronic cough may present as an independent symptom
[38]. Further, recent observations of chronic cough in sub-
jects without obvious respiratory disease such as asthma,
have suggested the existence of a distinct clinical entity, the
cough hypersensitivity syndrome [39,40]. The mechanisms
of idiopathic cough are unclear, but the enhanced cough
reflex in patients may result from increased sensitivity of
cough receptors such as TRPV1 [39]. In non-asthmatic
chronic cough patients, increased expression of TRPV1
was shown [3]. In our study, TRPV1 polymorphisms were
associated with cough, but only in subjects without asthma.
It is worth noting that associations with cough in those
without asthma hold for those without airflow limitation,
i.e. in subjects with cough independent of asthma or
COPD. Thus, it could be hypothesized that genetic varia-
tion in TRPV1 increases the risk of an enhanced cough
reflex among subjects without asthma. In asthmatics, the
situation may be more complex, and the (modest) effect of
genetic variation on TRPV1 channel activity may be
obscured by the influence of other mechanims such as air-
way inflammation. For example, in asthma patients,
chronic cough is associated with poor control of asthma
and the use of inhaled corticosteroids [41]. To further elu-
cidate the difference between subjects with and without
asthma, studies with more specific cough phenotypes
would be useful. Future replication studies could assess
whether TRPV1 polymorphisms may be associated with
greater cough sensitivity to inhaled capsaicin in cough
patients (with and without asthma). Such a study could
also include TRPV1 gene expression analysis before and
after capsaicin challenge.
Women have greater cough sensitivity to inhaled cap-
saicin than men, as was shown in cough patients and
healthy volunteers [42,43]. The reason for the greater
sensitivity among women is unknown, and it is unlikely
that smaller airway size and sex hormones explain these
differences [42,43]. In the present study, cough preva-
lence was also strongly associated with female sex, in par-
ticular among asthmatics, but the associations between
TRPV1 SNPs and cough symptoms were not different for
men and women.
We used occupational exposure to vapors, gases, dust,
and/or fumes as a proxy of work-related irritant expo-
sure. VGDF comprises a wide variety of exposures to
occupational agents, including irritants that may induce
cough by activation of TRP receptors. One can assume
that misclassification of irritant exposures by VGDF is of
a non-differential nature, resulting in estimated measures
of association that are biased toward the null, and a nega-
tive impact on the power to observe gene-environment
interactions between VGDF exposure and TRP variants.
Asthma was unrelated to VGDF exposure, a result con-
sistent with previous results [24]. However, exposure to
VGDF may modify the expression of asthma by increas-
ing cough, which appears to be long-lasting since not all
subjects were currently exposed. Long-term respiratory
effects of occupational irritant exposures have been
shown before, for example among women formerly
employed in domestic cleaning [22].
Conclusion
TRPV1 SNPs were associated with nocturnal, usual, and
chronic cough in subjects without asthma from two
independent studies in eight European countries. Irritant
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Page 8 of 11exposures such as cigarette smoking and occupational
exposures were associated with cough symptoms.
Exploratory findings on gene-environment interaction
suggested that these associations may be enhanced by
TRPV1 SNPs.
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